

Poster presentation

Socio psychiatric aspects of risperidone

Izabela Filov*¹, Mare Tumbevaska², Zivko Tumbevski², Laze Kuzmanovski²
and Dragan Janakievski²

Address: ¹Community Mental Health Prilep, F.Y.R.O.M and ²Mental Hospital Demir Hisar, F.Y.R.O.M

* Corresponding author

from International Society on Brain and Behaviour: 2nd International Congress on Brain and Behaviour
Thessaloniki, Greece. 17–20 November 2005

Published: 28 February 2006

Annals of General Psychiatry 2006, **5**(Suppl 1):S204 doi:10.1186/1744-859X-5-S1-S204

Background

Resocialisation process and techniques are the key point of interdependence of social psychiatry and psychopharmacology. Risperidon as a neuroleptic of new generation has shown more qualitative improvement in the extra hospital conditions than in conditions in hospital treatment.

Materials and methods

It was examined two groups of patients. The first group was from the 20 users in Community mental health, with diagnosis of schizophrenia and the second one was from the 20 patients, admitted with diagnosis of schizophrenia in Mental hospital. On the two groups were applied PANSS and CGI quertionarie.

Results

In the first group, results were: more quickly reduction of the psychotic symptoms, application of low doses of Risperidon (1.5–3 mg per day), much more qualitative remission. Also, it was not necessary to apply another neuroleptics.

Discussion

A combination of new neuroleptics (Risperidon) and resocialisation techniques and process, especillay in the extra hospital condition, is the treatment of choise in the present stage of knowledge. It helps a rational administration of psychotropics and use up patients vital existential potentialites.

References

1. Cadlovski G: *Clinical Psychopharmacology* 2003.
2. Kaplan H, Sadock B: *Comprehensive Textbook of Psychiatry* Third edition. 1998.
3. Hogarty GE, Anderson CM, Reiss DJ, et al.: **Family psychoeducation, social skills training and maintenance therapy in the**

4. **aftercare treatment of schizophrenia.** *Arch Gen Psychiatry* 1991, **48**:340-347.
Peuskens J, Risperidone Study Group: *Br J Psychiatry* 1995, **166**:712-726.